These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 30616755)

  • 41. Developing immunotherapeutic strategies to target brain tumors.
    Lieberman NA; Moyes KW; Crane CA
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):775-88. PubMed ID: 27253692
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
    Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
    Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
    Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
    Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
    Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
    Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM
    Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Armed hunter killers: discerning the role of adoptive T-cell transfer for glioblastoma.
    Samaha H; El Naggar S; Ahmed N
    Immunotherapy; 2015; 7(5):481-5. PubMed ID: 26065474
    [No Abstract]   [Full Text] [Related]  

  • 47. Metabolic therapy: a new paradigm for managing malignant brain cancer.
    Seyfried TN; Flores R; Poff AM; D'Agostino DP; Mukherjee P
    Cancer Lett; 2015 Jan; 356(2 Pt A):289-300. PubMed ID: 25069036
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
    Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
    World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma.
    Majd N; de Groot J
    Expert Opin Pharmacother; 2019 Sep; 20(13):1609-1624. PubMed ID: 31264484
    [No Abstract]   [Full Text] [Related]  

  • 50. New molecularly targeted therapies for glioblastoma multiforme.
    Polivka J; Polivka J; Rohan V; Topolcan O; Ferda J
    Anticancer Res; 2012 Jul; 32(7):2935-46. PubMed ID: 22753758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictive biomarkers investigated in glioblastoma.
    Tabouret E; Chinot O; Sanson M; Loundou A; Hoang-Xuan K; Delattre JY; Idbaih A
    Expert Rev Mol Diagn; 2014 Sep; 14(7):883-93. PubMed ID: 25096963
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
    Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
    Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comprehensive profile of recurrent glioblastoma.
    Campos B; Olsen LR; Urup T; Poulsen HS
    Oncogene; 2016 Nov; 35(45):5819-5825. PubMed ID: 27041580
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.
    Sengupta S; Mao G; Gokaslan ZS; Sampath P
    Cancer Gene Ther; 2017 Mar; 24(3):121-129. PubMed ID: 27767090
    [TBL] [Abstract][Full Text] [Related]  

  • 55. How We Treat Recurrent Glioblastoma Today and Current Evidence.
    Chaul-Barbosa C; Marques DF
    Curr Oncol Rep; 2019 Oct; 21(10):94. PubMed ID: 31606796
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
    Niyazi M; Harter PN; Hattingen E; Rottler M; von Baumgarten L; Proescholdt M; Belka C; Lauber K; Mittelbronn M
    Oncotarget; 2016 Jan; 7(3):2313-28. PubMed ID: 26575171
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
    Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
    Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Suppressive immune microenvironment and CART therapy for glioblastoma: Future prospects and challenges.
    Lu J; Huo W; Ma Y; Wang X; Yu J
    Cancer Lett; 2024 Sep; 600():217185. PubMed ID: 39142498
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
    Desland FA; Hormigo A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-angiogenic gene therapy in the treatment of malignant gliomas.
    Gatson NN; Chiocca EA; Kaur B
    Neurosci Lett; 2012 Oct; 527(2):62-70. PubMed ID: 22906922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.